Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vivoryon Therapeutics NV's Enterprise Value is €30.60 Mil.
Vivoryon Therapeutics NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.81 Mil. Therefore, Vivoryon Therapeutics NV's EV-to-EBIT ratio for today is -3.47.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Vivoryon Therapeutics NV (LTS:0R3M) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Vivoryon Therapeutics NV's EV-to-EBIT for today is
Vivoryon Therapeutics NV's current Enterprise Value is €30.60 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vivoryon Therapeutics NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.81 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Vivoryon Therapeutics NV's EV-to-EBITDA for today is:
Vivoryon Therapeutics NV's current Enterprise Value is €30.60 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vivoryon Therapeutics NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.66 Mil.
Vivoryon Therapeutics NV's current Enterprise Value is €30.60 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vivoryon Therapeutics NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.
Vivoryon Therapeutics NV's current Enterprise Value is €30.60 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vivoryon Therapeutics NV's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.46 Mil.
Vivoryon Therapeutics NV's current Enterprise Value is €30.60 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vivoryon Therapeutics NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivoryon Therapeutics NV Enterprise Value Related Terms
Vivoryon Therapeutics NV Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R3M vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Vivoryon Therapeutics NV's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivoryon Therapeutics NV Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Vivoryon Therapeutics NV's Enterprise Value falls into.
Vivoryon Therapeutics NV Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Vivoryon Therapeutics NV's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivoryon Therapeutics NV (LTS:0R3M) has a Enterprise Value of €30.60 Mil as of Jul. 21, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Vivoryon Therapeutics NV and its competitors.
Is Vivoryon Therapeutics NV's Enterprise Value too high?
Vivoryon Therapeutics NV's current Enterprise Value is €30.60 Mil. Overall, Vivoryon Therapeutics NV has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's Enterprise Value compare to VRTX and REGN?
Vivoryon Therapeutics NV's Enterprise Value of €30.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Vivoryon Therapeutics NV and its competitors. Vivoryon Therapeutics NV's current Enterprise Value is €30.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (LTS:0R3M) has a current Enterprise Value of €30.60 Mil. The current Enterprise Value is €30.60 Mil. Vivoryon Therapeutics NV's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Vivoryon Therapeutics NV (LTS:0R3M), the current Enterprise Value is €30.60 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
32GF Score
Get the complete analysis for LTS:0R3M
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R3M has been successfully added to your 
